L-Glutamine: IBS, IBD, Safety and Evidence Limits

L-glutamine helps supply intestinal and immune-cell metabolism; biological plausibility does not establish a supplement benefit (mechanistic review). Human findings depend on the setting: Zhou studied selected post-infectious IBS-D, Rastgoo tested a low-FODMAP add-on, and the Crohn’s review found evidence too sparse for firm efficacy or safety conclusions. REDOXS identified harm with a high-dose combined-route ICU protocol. These different populations, routes and outcomes should not be merged into a universal verdict. This article examines the cited forms, studies, safety limits and declared financial relationships.

Table of contents

• Evidence summary
• What L-glutamine is
• Forms and formulations
• How it works
• Intestinal permeability and "leaky gut"
• Irritable bowel syndrome (IBS)
• Inflammatory bowel disease — Crohn’s disease
• Ulcerative colitis and IBD broadly
• Critical illness, trauma, burns, and surgery
• Exercise, immune function, and muscle
• Sickle cell disease and "FDA-recognized" marketing
• Claim-by-claim assessment
• Risks and reported adverse effects
• Interactions and unstudied combinations
• Who needs clinical assessment
• Dosage and how to take it
• Funding tracing and regulatory status
• Frequently asked questions
• Sources and funding notes

What L-glutamine is

L-glutamine is a major free amino acid in plasma and skeletal muscle. The body synthesises it, but production and demand can become mismatched during severe catabolic illness. This is the basis of the term “conditionally essential”; it does not itself show that supplemental glutamine improves clinical outcomes (Kim and Kim 2017; Cruzat 2018).

Intestinal and immune cells use glutamine as a metabolic fuel. This provides a rationale for studying gut-barrier and immune claims, rather than proof that adding more improves a healthy person’s gut. Cruzat’s narrative review combines mechanistic and heterogeneous clinical evidence; it is not a systematic survey of every marketing claim (Cruzat 2018).

Forms and formulations

The studied preparation and route matter. Free powder and dipeptide quantities should not be treated as equal grams of glutamine. The clinical IV trials and oral IBS protocols are different interventions; chemical stability alone does not establish equal efficacy, safety or an oral form ranking (IBD formulations; dipeptide chemistry; oral IBS trial).

How it works

Enterocytes and other rapidly dividing cells (including many immune cells) preferentially oxidize glutamine for energy, more so than glucose in some contexts. The proposed mechanism behind gut-barrier claims is that adequate glutamine supply supports enterocyte energy metabolism, proliferation, and tight-junction integrity, which in principle could reduce intestinal permeability under conditions of gut stress (Cruzat et al., Nutrients 2018; Kim & Kim, Int J Mol Sci 2017). Much of the detailed cell-biology and gut-integrity mechanism data underpinning this story comes from rodent and cell-culture models; that mechanistic work is not used here to support any human efficacy or safety conclusion and is noted only as background for why the claim is biologically plausible.

Glutamine contributes to immune-cell metabolism and glutathione synthesis. These pathways helped motivate clinical testing, but a biochemical rationale is not a clinical benefit: ICU results differ with population and protocol (mechanistic review; REDOXS; SIGNET). See the critical-care evidence below.

Intestinal permeability and "leaky gut"

This selected IBS-D population has a notable publicly funded glutamine trial; its results do not establish benefits for general gut-healing claims. (Primary source)

Zhou's eight-week, double-blind trial enrolled adults with post-infectious IBS-D and measured hyperpermeability at two US centers. It randomized 115; the reported analysis included 106 completers. Glutamine was 5 g three times daily, compared with whey-protein powder. A ≥50-point symptom-score reduction occurred in 43/54 (79.6%) versus 3/52 (5.8%). Permeability improved, but this selected sample, completer analysis and active comparator limit generalization (Zhou 2019).

Zhou’s own limitations identify a selected post-infectious IBS-D population and the need for further confirmation. The study used a urinary lactulose/mannitol research threshold; it does not validate every commercial “leaky gut” test or treatment. Nine randomized participants were not in the reported completer analysis, and the comparator was whey powder, not an inert substance (Zhou 2019).

The reviewed trials do not establish glutamine-driven gut repair for healthy people or nonspecific digestive complaints. Cell and animal findings explain plausibility but cannot settle human symptom benefit, dose or safety. The selected IBS-D result should not be generalised to everyone using the phrase “leaky gut” (selected trial; mechanistic review).

Irritable bowel syndrome (IBS)

Rastgoo 2021 randomized 50 adults with IBS; 44 completed. Both arms followed a low-FODMAP diet for six weeks, adding 15 g/day glutamine or whey powder. The intention-to-treat analysis used five multiple-imputation datasets: more than 45% symptom-score improvement occurred in 22/25 (88%) versus 15/25 (60%), p=0.015. Adjusted quality-of-life and stool outcomes did not show an added benefit. Shahid Beheshti University of Medical Sciences funded the study; no commercial/financial conflicts were declared. The small sample, active comparator and shared diet limit generalisation; powder procurement terms and the full registered protocol remain unestablished.

Inflammatory bowel disease — Crohn’s disease

The 2016 Cochrane review searched through November 2015 and included an 18-child diet trial and a 24-adult parenteral trial (19 Crohn’s, five ulcerative colitis). Only the child trial measured remission: 4/9 versus 5/9, RR 0.80 (95% CI 0.31–2.04), graded low certainty because of serious imprecision. Neither trial found a between-group permeability improvement. Different interventions prevented pooling, and adverse effects were poorly documented; efficacy and safety remain uncertain.

The review group reported CIHR and Ontario public support. Akobeng was an investigator in an included trial; Gordon disclosed pharmaceutical and nutrition-company travel grants outside this work. These relationships should be considered separately from the low-certainty clinical findings (Cochrane 2016).

Ulcerative colitis and IBD broadly

Severo’s review selected seven reports of oral, enteral or parenteral glutamine in IBD, including a six-person uncontrolled glutamine-plus-antioxidant pilot. Its body reports isolated favorable findings, but permeability improved in both glutamine and whey-protein comparator groups in one trial, and the combination pilot cannot isolate glutamine’s effect. These small, heterogeneous reports do not establish consistent clinical benefit or prove that every measured outcome was unchanged (Severo 2021; author journal pre-proof).

Academic affiliation is not an independence certificate. Severo’s author pre-proof reports CAPES and University Hospital/Federal University of Piauí research-programme support and no conflicts. The definitive final version, full underlying-trial finances and cohort overlap have not been independently reconstructed. These limits are separate from the small, heterogeneous clinical findings (author pre-proof).

Critical illness, trauma, burns, and surgery

Critical-care trials provide important evidence about specific hospital protocols. They are not trials of healthy people taking ordinary oral powders. Dose, route, timing, organ failure and standard nutrition differ; their mortality findings should be applied within those studied settings.

REDOXS 2013 randomized 1,223 patients across 40 ICUs; 1,218 were in the final intention-to-treat analysis. Mechanically ventilated adults with at least two organ failures received early high-dose combined IV/enteral glutamine or placebo, independently of standard nutrition. Primary 28-day mortality was 32.4% versus 27.2% (adjusted OR 1.28, 95% CI 1.00–1.64, p=0.05), failing the prespecified p<0.044 threshold. In-hospital mortality was 37.2% versus 31.0%, and six-month mortality 43.7% versus 37.2% (both p=0.02). No organ-failure or infection benefit was detected. These endpoint-specific results do not justify a general claim about typical oral supplement doses.

SIGNET randomized 502 critically ill adults requiring parenteral nutrition across ten Scottish centres. Glutamine, 20.2 g/day for up to seven days, did not significantly reduce new infections or mortality. The SIGNET full report reports MRC funding for the full trial, Scottish public support, and unrestricted nutrition-component grants from Fresenius Kabi and Oxford Nutrition. Authors reported independent management and no competing interests.

Sun’s 2021 review included 47 trials (6,198 patients), searching through June 2017. Overall hospital mortality was not significantly reduced; ventilation duration was shorter, while overall infection and length-of-stay results were nonsignificant. An older burn-subgroup signal was exploratory context, not a current treatment guarantee. Chen’s 2014 review likewise found no overall mortality benefit, but retained a significant pooled infection reduction. These are distinct endpoints. Sun declared no funding/no conflicts; Chen declared National Natural Science Foundation of China support/no conflicts. Constituent-trial finances remain a separate, incomplete assessment.

RE-ENERGIZE 2022 randomized 1,209 severe-burn patients and analysed 1,200. Enteral glutamine did not significantly shorten discharge alive (median 40 versus 38 days; HR 0.91, 95% CI 0.80–1.04) or change six-month mortality (17.2% versus 16.2%). Its primary endpoint changed from mortality to discharge alive during low recruitment using blinded data. US Defense and CIHR funded it; Emmaus provided trial agents. Supporters were declared to have no study role or prepublication data access; individual author forms and supply payment terms remain unverified. ESPEN 2023 advises against additional enteral glutamine outside burn/trauma groups and parenteral dipeptide in unstable, complex ICU patients, particularly with liver/renal failure. It retains a burn recommendation while acknowledging that RE-ENERGIZE challenges it and revision is needed. This is route- and setting-specific guidance.

Exercise, immune function, and muscle

Lu 2024 studied 21 young combat-sport athletes in a randomized crossover using 0.3 g/kg/day for three weeks versus maltodextrin. It reported five versus 12 symptom-defined respiratory illnesses and salivary changes. Illnesses were self-reported, not laboratory-confirmed, and sport performance was not measured. Washout, blinding and crossover-analysis reporting were unclear; small short-term findings do not establish general recovery, muscle-preservation or performance benefit. Taiwan MOST/NSTC grants supported it; no conflicts were declared. Product source/payment terms were not established.

Sickle cell disease and "FDA-recognized" marketing

Prescription Endari is approved to reduce acute complications of sickle cell disease in adults and children aged five and older. The June 2025 FDA label reports a 230-patient phase-three study: median crises were three versus four, and median hospitalisations two versus three during 48 weeks. The label’s outcome analysis and approved indication are condition-specific; no formal certainty grade is assigned here. Approval does not extend to IBS, “leaky gut” or retail gut-healing powders. FDA listing of an ingredient for a conditional food use is a different regulatory question.

Claim-by-claim assessment

Risks and reported adverse effects

Interactions and unstudied combinations

Who needs clinical assessment

• Advanced cirrhosis requires particular caution: small oral-challenge studies cited by LiverTox found worsened ammonia handling and some psychometric measures. Discuss supplementation with the treating clinician.
• For kidney impairment, discuss the dose and preparation with the treating clinician. Endari’s pharmacokinetics were not studied in renal or hepatic impairment, and the selected IBS-D trial excluded these diseases. ESPEN’s warning is specifically about parenteral dipeptide in unstable/complex ICU patients (FDA label; IBS exclusions; ESPEN).
• Critical illness with multiorgan failure requires specialist nutrition decisions. REDOXS found harm with early high-dose combined IV/enteral glutamine; ESPEN advises against parenteral dipeptide in unstable, complex ICU patients, particularly with liver/renal failure. Its separate burn/trauma recommendations cannot be replaced by a universal glutamine rule (REDOXS; ESPEN 2023).
• A reaction to MSG cannot be assumed to predict a reaction to glutamine. Direct human evidence for that cross-sensitivity has not been established here.
• Selected IBS trials do not establish glutamine alone for all IBS or nonspecific “leaky gut.” The Rastgoo 2021 add-on result is limited by its diet co-intervention and small sample. Glutamine should not replace established IBD care.

Dosage and how to take it

Funding tracing and regulatory status

Declared financial support and remaining limits

Stehle and Kuhn’s 2015 narrative review lists both authors as Fresenius Kabi Deutschland consultants and says Kuhn received remuneration. It is not a current formal guideline. Mulherin and Sacks’ editorial also reports Fresenius Kabi USA consulting payment to Sacks, alongside a generic no-conflict statement. These financial facts should be visible; they do not by themselves explain trial results or establish bias (Stehle and Kuhn; Mulherin and Sacks).

Public funding is not a guarantee of independence or correctness. REDOXS had CIHR funding plus a Fresenius Kabi unrestricted grant and glutamine supply; Biosyn supplied IV selenium at European sites. Investigators reported control over study decisions. Its high-dose, combined IV/enteral regimen in critically ill adults produced significant in-hospital and six-month mortality increases, although the 28-day trend (p=0.05) did not meet the prespecified p<0.044 threshold. Funding and conflicts must be assessed study by study. Heyland et al. 2013

Regulatory status

• US food use: FDA’s substance listing points to 21 CFR 172.320. The official 2025 section lists L-glutamine and conditional nutrient use, including protein-quality, quantity, recordkeeping and labelling requirements; it has a specific medical-supervision exception. This is not blanket GRAS status, supplement approval or permission to treat gut disorders. The current eCFR delivery was unavailable; the official annual text is the verified document here.
• Prescription Endari is approved to reduce acute complications of sickle cell disease in adults and children aged five and older. Its drug indication and trial evidence do not authorise gut-health claims for supplements (FDA June 2025 label).
• EU: food supplements are regulated as foods, and ingredient safety and health-claim authorization are separate matters. The EFSA food-supplement overview does not establish blanket glutamine authorization across food, supplement and parenteral uses. Product and national rules require separate verification.

Frequently asked questions

Does L-glutamine heal "leaky gut"?

The selected post-infectious IBS-D trial reported improved urinary permeability and a large symptom-score response among completers after 15 g/day for eight weeks versus whey. That is promising evidence in a narrow setting, not proof of broad “leaky gut” repair or validation of every commercial permeability test. Generalisation and replication remain unresolved (Zhou 2019).

Does glutamine help Crohn’s disease or ulcerative colitis?

The Cochrane review found remission evidence too sparse for firm conclusions. The Severo IBD review did not establish consistent clinical benefit across its small, mixed reports; some individual outcomes favoured glutamine. These findings leave uncertainty and do not justify replacing established IBD treatment.

Is L-glutamine dangerous?

Safety depends on the person, dose, route and protocol. Zhou’s selected IBS-D trial reported low short-term adverse-event rates at 15 g/day; REDOXS found increased in-hospital and six-month mortality with high-dose combined IV/enteral treatment in ICU patients. These do not establish universal oral safety or harm. Endari’s label reports trial-specific adverse effects, no drug-interaction studies, and unstudied renal/hepatic pharmacokinetics. Pregnancy/lactation data are absent and older-adult evidence limited; these groups require individual clinical assessment (IBS trial; REDOXS; FDA label).

Is L-glutamine FDA-approved?

The official 2025 food-additive rule allows conditional nutrient food use; it does not approve a dietary supplement for IBS or “leaky gut.” The Endari label separately approves that prescription drug for reducing acute SCD complications in people aged five and older. Ingredient permission and disease-treatment approval are different questions.

Should critically ill patients take glutamine?

REDOXS found harm with its high-dose combined-route protocol, while RE-ENERGIZE did not confirm the older burn benefit. ESPEN 2023 makes route- and patient-specific recommendations; it retains a burn recommendation while explicitly acknowledging that newer evidence challenges it and revision is needed. ICU nutrition requires specialist decisions.

Does glutamine help athletes or exercise recovery?

The reviewed sources do not establish broad recovery, muscle-preservation or performance benefit. Lu’s small crossover reported fewer symptom-defined respiratory illnesses; it did not measure sport performance and had reporting limits. Cruzat is a narrative mechanism/clinical review, with university support, rather than an independent systematic athlete-outcome census (Lu 2024; Cruzat 2018).

Sources and funding notes

• Zhou Q, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019. PMID 30108163
• Ford AC, Gibson PR. Efficacy of glutamine in postinfection IBS. Gut. 2019. Comment, PMID 30244201. Full comment unavailable; only identity and public primary conflict disclosure assessed. Gibson’s institutional industry advisory/research and low-FODMAP publication/application interests are disclosed.
• Akobeng AK, Elawad M, Gordon M. Glutamine for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2016. PMID 26853855 (full text, PMC10405219)
• Severo JS, et al. Effects of Glutamine Supplementation on Inflammatory Bowel Disease: A Systematic Review of Clinical Trials. Clinical Nutrition ESPEN. 2021. PMID 33745622. Complete author accepted pre-proof; definitive final-version access remains unresolved.
• Heyland D, et al. A randomized trial of glutamine and antioxidants in critically ill patients (REDOXS). New England Journal of Medicine. 2013. PMID 23594003
• Mulherin DW, Sacks GS. Uncertainty about the safety of supplemental glutamine: an editorial on “A randomized trial of glutamine and antioxidants in critically ill patients”. Hepatobiliary Surgery and Nutrition. 2015. Sacks disclosed Fresenius Kabi USA consulting payment.
• Andrews PJD, et al. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients (SIGNET). BMJ. 2011 (PMID 21415104)
• Sun Y, et al. Glutamine on critical-ill patients: a systematic review and meta-analysis. Annals of Palliative Medicine. 2021. PMID 33222464. No funding/conflicts declared; search through June 2017.
• Chen QH, et al. The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. Critical Care. 2014. NSFC support; no conflicts declared. Mixed routes and outcomes; underlying trial finances remain untraced.
• Kim MH, Kim H. The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. International Journal of Molecular Sciences. 2017. Brain Korea 21 PLUS/Yonsei support; no conflicts declared. Mechanistic/clinical narrative context.
• Cruzat V, et al. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. 2018. Torrens financial research support and Curtin research facilities acknowledged; no conflicts declared. Not a systematic athlete efficacy review.
• Parry-Billings M, et al. Plasma amino acid concentrations in the overtraining syndrome. Medicine & Science in Sports & Exercise. 1992. PMID 1470018. Abstract/metadata only; original finance and full methods unavailable. Observational context, not a glutamine supplement efficacy trial.
• Lu YC, et al. Supplementation of L-glutamine enhanced mucosal immunity and improved hormonal status of combat-sport athletes. Journal of the International Society of Sports Nutrition. 2024. Taiwan MOST/NSTC grants; no conflicts declared. Small crossover; reporting and product-procurement gaps remain.
• LiverTox: L-Glutamine. NIH National Library of Medicine. NBK573011
• Hatami B, et al. Glutamine powder-induced hepatotoxicity: it is time to understand the side effects of sports nutritional supplements. 2020. PMC7069532. No conflicts declared; no explicit funding located. Single sports-product case with unresolved composition and inconsistent dose, not validated high-dose glutamine causality.
• Rama Rao KV, Norenberg MD. Glutamine in the Pathogenesis of Hepatic Encephalopathy: The Trojan Horse Hypothesis Revisited. Neurochemical Research. 2014 (online 2013). NIH/VA support; separate conflict declaration not located. Mechanistic context, not an oral drug-interaction trial.
• Stehle P, Kuhn KS. Glutamine: an obligatory parenteral nutrition substrate in critical care therapy. BioMed Research International. 2015:545467. Both authors were Fresenius Kabi Deutschland consultants; Kuhn remuneration disclosed. Historical narrative, not current formal guidance.
• Fürst P, et al. Glutamine-containing dipeptides in parenteral nutrition. 1990. PMID 2119457. Original abstract only; complete text and named funding/COI unavailable. Chemistry/delivery context, not an oral efficacy ranking.
• FDA. Substances Added to Food: L-Glutamine; 21 CFR 172.320, official 2025 section. Conditional food-use records, not a glutamine supplement efficacy approval.
• EFSA. EFSA food-supplement overview; general regulatory overview, not glutamine-specific efficacy approval.
• RE-ENERGIZE 2022 — Heyland et al., NEJM 2022. US Defense/CIHR support; Emmaus supplied agents. No supporter role/prepublication access declared; individual author forms and supply-payment terms unavailable.
• ESPEN 2023 ICU guideline — Singer et al., Clinical Nutrition 2023. ESPEN-funded process; route/patient-specific recommendations, with retained burn recommendation challenged by newer evidence. Full author/society financial chains not reconstructed.
• Rastgoo et al. 2021. Six-week low-FODMAP add-on trial; Shahid Beheshti University of Medical Sciences support, no commercial/financial conflicts declared. ITT multiple imputation; powder/payment terms unresolved. Endari FDA prescribing information, June 2025 supplies prescription indication, population and interaction-study limits, not gut-supplement efficacy.